ERBB2 and neoplasm: For the trastuzumab-treated group, fewer T cells were detected, and there was rare infiltration by DCs (Fig. 4D).These results indicate that the HCI fusion protein can simultaneously recognize the HER-2 antigen of gastric cancer cells and carry effector molecules to tumor tissues, which can induce chemotactic and activated immune molecules to migrate to tumor tissues, break the immune suppression of the tumor microenvironment, and play an antitumor role.